Equity · Healthcare
AXSM
NASDAQAxsome Therapeutics (AXSM)
The line runs 215 USD on 12 August through 133.88 USD on 9 November, on a scale from 125 to 225. Days the market did not trade hold the previous close, flat.
- Market cap
- 7.0B USD
- Revenue, year to Dec 2025
- 638.5M USD
- EPS, diluted, year to Dec 2025
- −3.68 USD
- 52-week range
- 129.90 USD – 255 USD
- Avg volume
- 76.0K
as of Nov 9, 2026
Have Axsome Therapeutics (AXSM) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Axsome Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 6 Oct 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 3 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Sep 2026 | Jacobson Mark L.Chief Operating Officer | Sell | 10,000 | 2.1M USD |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 03 Sep 2026 | Jacobson Mark L.Chief Operating Officer | Option exercise | 10,000 | 130K USD |
Which funds hold Axsome Therapeutics (AXSM)?
12 of the 45 institutional funds we track reported a Axsome Therapeutics position for the quarter ended 30 Jun 2026 — a combined 817.1M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Added | 669,478 | 163.9M USD | +107.4% |
| D. E. Shaw & Co. | Held (±25%) | 604,753 | 148.0M USD | +0.2% |
| Millennium Management | Added | 556,088 | 136.1M USD | +2,578.9% |
| Point72 Asset Management | Held (±25%) | 416,516 | 102.0M USD | −1.9% |
| Renaissance Technologies | Added | 262,000 | 64.1M USD | +59.5% |
| Citadel Advisors | Held (±25%) | 255,878 | 62.6M USD | −9.1% |
| Marshall Wace | Added | 223,386 | 54.7M USD | +58.2% |
| AQR Capital Management | Held (±25%) | 114,025 | 27.9M USD | +9.6% |
| Man Group | Trimmed | 82,526 | 20.2M USD | −42.0% |
| Balyasny Asset Management | New position | 76,250 | 18.7M USD |
Showing the 10 largest of 12 reported positions. The figures above count all of them.
What has been filed or recorded for Axsome Therapeutics (AXSM)?
The filings we hold for Axsome Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 13 Oct 2026 | Fails to deliver | Shares failed to deliver | 649 shares | 108K USD notional · 0.001% of shares out |
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,786 shares | 304K USD notional · 0.003% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 26 shares | 5K USD notional · <0.001% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.25 USD | |
| 30 Sep 2026 | Financials | Total assets | 826.8M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 105.4M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.99 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −1.26 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.68 USD | |
| 31 Dec 2025 | Financials | Revenue | 638.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −183.2M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.68 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.94 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.97 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.22 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −5.99 USD |
What do people ask about Axsome Therapeutics (AXSM)?
What did Axsome Therapeutics shares close at?133.88
Axsome Therapeutics closed at 133.88 USD on 9 Nov 2026, up 1.19% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Axsome Therapeutics’ market cap?7.0B
Axsome Therapeutics is worth 7.0B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Axsome Therapeutics’ revenue?638.5M
Axsome Therapeutics reported revenue of 638.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Axsome Therapeutics insiders bought or sold shares recently?1 sale
In the 90 days to 10 Nov 2026, Axsome Therapeutics insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 6 Oct 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Axsome Therapeutics?12 of 45
12 of the 45 funds we track reported a Axsome Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, D. E. Shaw & Co. and Millennium Management. See Funds
When did Axsome Therapeutics last report earnings?−0.25
Axsome Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.25 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings